Invitation: From July 19 to July 21, ≈ ≈£2023, Haibu invites y∏✔ou to Beijing, China for the &q<™©uot;Frontier Technology S♥•ummit on Drug Formulati↓₽on".
Classification:
Recent Events
Release time:
2023-09-18
- Conference Time:July 20-21, 2023
- Conference Location:Crowne Plaza Beijing Lido, Ch λ$÷ina
- Haibu Booth:No. 5
- Speech Topic:"Focus Points in the Pharmaceutical Dev→→elopment of Pediatriσ₽c Transdermal Preparations"
- Speech Time:間(jiān): July 21, 2023, 11:20-11:5α''§0
Speaker:Dr. Diwei
, Deputy General Manager of Beijing♠" Haibu Pharmaceutical;, PhD from the Academ♣§¶y of Military Medical S★•¥ciences of the PLA.
- , previously worked at the N¶≤♦αational Medical Products Administratio ¶≥n, participated in the review of m$'ultiple innovative d≠✔£∞rugs and the drafting of several≤÷← guidelines;評及多(duō)個(gè)指導原則的(de)撰寫工(gōng)作(zu✘≤γò)；
- , has engaged in R&D and management ε₽♦ work for various innovative a✘¥←βnd generic drugs, obtaining multiple¶≈ patent authorizations and r♦ egistration approvals;得(de)多(duō)項專利授權和(hé)注冊批件(jiàn)；
- , currently serves as Deputy General ≥®Manager of Beijing Hai¥<♥bu Pharmaceutical Technology Co., Ltd.,®¶β mainly responsible for the R&£&σD management of innov☆γεγative drugs and improved new dru÷ γgs, as well as intel§♦ lectual property and cliniσ×→€cal registration application man ♣♦εagement.責創新藥、改良型新藥的(de)研發管理(lǐ)工(gōng)作(zuò)， ♥ε以及知(zhī)識産權和(hé)臨床注冊申報(bào)管理(€₩©&lǐ)等工(gōng)作(zuò)。
(Beijing Haibu Pharmaceutical Techno☆↓logy Co., Ltd. (referred to as "Haibu P≠÷harmaceutical") was est ₹±ablished in 2005 and is a high-♣≤tech enterprise with "chemical drug∑δ¥ R&D" as its core ♠£<§capability. It has a research×β±π and development center in Beiφ∏♦jing, an API and formulation pilot vαerification center, an←€d a GMP industrial productiφπ↑÷on base, mainly engaged in CR÷®O services for APIs an←¶¥&d formulations, MAH joi÷♣nt licensing, API-related applic✘™ations, and commercial supply of pharmπ≠↓aceutical intermediates.)
在化(huà)學原料藥、口服固體(tǐ)、液體(tǐ)制(zhì)劑>↑€、無菌注射劑、外(wài)用(yòng)制(zhì)劑等多(duπō)種劑型的(de)研發轉産、注冊申報(bào)等方面經驗豐富。研發産品涉及抗"↕✔腫瘤、抗抑郁、抗癫痫、抗焦慮、心腦(nǎo)血管、消化♠ ≤(huà)系統、呼吸系統等多(duō)個(↓α$gè)适應症領域。
(Haibu Pharmaceutical has rich expΩ↓•∑erience in the R&D transfer prod₽£uction, registration applicatio&₹<n, etc., of various dosa♥✔ge forms such as che±"₽mical APIs, oral solids §☆, liquid preparations,€€±★ sterile injections, exte←π• rnal preparations. The≤π R&D products coveΩ≈σ₹r multiple therapeutic areas inclσuding anti-tumor, anti-depreφ€↔ssion, anti-epilepsy, an↓ ti-anxiety, cardiovascu≠γlar diseases, digestive system dαεiseases, respiratory system d≥←iseases.)
Beijing Hope Pharmaceutical Co., Lt ©¶>d.
